Asia Deal Watch: Otsuka Gets Japanese Rights To Perception’s Mood Disorder Candidate
Plus deals involving I-Mab/Complix, Lupin/Endoceutics, Genome & Co/Pfizer/Merck KGaA, Genome & Co/Debiopharm, Exelixis/WuXi, Intas/Foresee, Wugen/Alpha Biosciences
You may also be interested in...
Pfizer has announced plans to put a lid on its biosimilars programs in China, while agreeing the sale of its manufacturing site in Hangzhou.
Samsung Bioepis has added its Adalloce adalimumab version of Humira to its Korean biosimilars partnership with Yuhan Corporation, ahead of an imminent launch.
Private equity investor Advent has acquired API maker ZCL Chemicals in India, its second transaction in a segment seeing rising interest as pharma de-risks sourcing for key ingredients post COVID-19-related turbulence.